Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant cisplatin-based chemotherapy versus observation in resected low-SUV non-small-cell lung cancer
NL-OMON27925Phase 3Suspended
- Sponsor
- NVALT
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, docetaxel, gemcitabine, pemetrexed and vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NVALT. Primary endpoint: Recurrence-free survival. Started Jan 2007; status: suspended.
02
Drugs
cisplatindocetaxelgemcitabinepemetrexedvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON27925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27925.